Pfizer Inc 8-K Filing
Ticker: PFE · Form: 8-K · Filed: Dec 16, 2025 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.05 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Pfizer Inc (ticker: PFE) to the SEC on Dec 16, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.05 (ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange).
How long is this filing?
Pfizer Inc's 8-K filing is 2 pages with approximately 587 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2025-12-16 07:01:53
Key Financial Figures
- $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange
Filing Documents
- pfe-20251216.htm (8-K) — 37KB
- pfe-12162025xexh99.htm (EX-99.1) — 76KB
- pfizerlogo.jpg (GRAPHIC) — 38KB
- 0000078003-25-000167.txt ( ) — 349KB
- pfe-20251216.xsd (EX-101.SCH) — 3KB
- pfe-20251216_def.xml (EX-101.DEF) — 17KB
- pfe-20251216_lab.xml (EX-101.LAB) — 31KB
- pfe-20251216_pre.xml (EX-101.PRE) — 18KB
- pfe-20251216_htm.xml (XML) — 7KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 16, 2025, Pfizer Inc. issued a press release that provided its full-year 2026 guidance and revised its full-year 2025 Revenue guidance while reaffirming all other components of its full-year 2025 financial guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information furnished pursuant to this "Item 7.01 – Regulation FD Disclosure", including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description Exhibit 99.1 Press Release of Pfizer Inc. dated December 16, 2025 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: December 16, 2025